The company's biopharma business grew 280 percent year over year, including contributions from Gentris, which Cancer Genetics bought last summer.
The company drew a first tranche of $8.5 million from the credit facility in July and has $2 million remaining on the term loan commitment.
The technical-only testing service leverages Ventana's digital pathology technology.
The decision opens up the largest market in the country to the firm's lymphoma and leukemia testing services.
The firm was not in compliance with minimum bid price and minimum stockholders' equity requirements to remain listed.
Cancer Genetics CEO Panna Sharma told GenomeWeb this week that the company plans to focus on very targeted panels of actionable mutations.
The company has been told by Nasdaq that it falls short of a listing requirement for at least $2.5 million in stockholders' equity.
The company can now market and report results from its ResponseDX tests to residents of New York.
NEW YORK (GenomeWeb) – Response Genetics today said that its third quarter revenues rose 9 percent year over year on higher testing revenues and volumes.
NEW YORK (GenomeWeb) – Cancer Genetics said today that its third quarter revenues shot up 88 percent year over year on clinical testing volume growth and the close of two acquisitions during the quarter.
The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.
In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.